A Single-Arm, Multicenter, Phase II Study of MRG003 Combined With QL1706 for Second-Line or Later Treatment of Recurrent or Metastatic Cervical Cancer (ASCERV Study)
Latest Information Update: 27 Apr 2026
At a glance
- Drugs Becotatug vedotin (Primary) ; Iparomlimab/tuvonralimab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ASCERV Study
Most Recent Events
- 27 Apr 2026 New trial record